Trial Profile
Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies.
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs FP 1039 (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- 11 Oct 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 16 Jun 2012 Planned number of patients changed from 72 to 54 and official title amended as reported by ClinicalTrials.gov.
- 16 Jun 2012 Investigational drug (Pemetrexed) has been removed as reported by ClinicalTrials.gov.